Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-miR-155-5p APAF1 2.81 7.0E-5 0.35 0.33131 miRNAWalker2 validate -0.11 0.0002 22996741; 26877850 MiR 155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf 1 expression; The objective of this study is to verify the hypothesis based on the results of bioinformatics analysis that miR-155 modulates cellular apoptosis and DNA damage through the regulation of Apaf-1 and is thus involved in the development and progression of lung cancer; First we measured the expression of miR-155 and the Apaf-1 protein in lung cancer tissues; The results showed that expression of miR-155 was significantly higher in lung cancer tissues than in paracancerous and normal tissues; whereas Apaf-1 expression was lower in the lung cancerous tissues; The results showed that relative to controls the silencing of miR-155 resulted in elevated expression of the Apaf-1 protein whereas Apaf-1 mRNA levels remained unchanged; Both the silencing of miR-155 and the overexpression Apaf-1 greatly increased the sensitivity of A549 cells to cisplatin treatment as evidenced by elevated rates of apoptosis and DNA damage; Furthermore dual-transfection of A549 cells with miR-155 siRNA and Apaf-1 siRNA resulted in the attenuation of apoptosis and DNA damage;Also increase in the transcript level of APAF-1 and CASP-9 after downregulation of miR-21 and miR-155 might indicate that these genes were targeted by aforementioned miRNAs in T47D cells
2 hsa-miR-23a-3p APAF1 0.93 0.01273 0.35 0.33131 miRNATAP -0.25 1.0E-5 24992592; 24249161 Luciferase assay was performed to verify a putative target site of miR-23a in the 3'-UTR of apoptosis protease activating factor 1 APAF1 mRNA; The expression levels of miR-23a and APAF1 in CRC cell lines SW480 and SW620 and clinical samples were assessed using reverse transcription-quantitative real-time PCR RT-qPCR and Western blot; Moreover miR-23a up-regulation was coupled with APAF1 down-regulation in CRC tissue samples;We found that the expression of miR-23a was increased and the level of apoptosis-activating factor-1 APAF-1 was decreased in 5-FU-treated colon cancer cells compared to untreated cells; APAF-1 as a target gene of miR-23a was identified and miR-23a antisense-induced increase in the activation of caspase-9 was observed
3 hsa-miR-23b-3p APAF1 -0.58 0.19048 0.35 0.33131 miRNATAP -0.16 0.00048 NA
4 hsa-miR-27a-3p APAF1 1.76 0.00022 0.35 0.33131 miRNATAP -0.18 3.0E-5 NA
5 hsa-miR-27b-3p APAF1 -0.09 0.85847 0.35 0.33131 miRNATAP -0.16 6.0E-5 NA
6 hsa-miR-590-3p APAF1 2.35 0 0.35 0.33131 PITA; miRanda; mirMAP; miRNATAP -0.12 0.0034 NA
7 hsa-miR-708-3p APAF1 0.78 0.29065 0.35 0.33131 mirMAP -0.12 2.0E-5 NA
8 hsa-miR-203a-3p ATM 6.35 0 -0.66 0.11688 MirTarget -0.11 0 24145123; 27542403 miR 203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase; In silico analysis identified ataxia telangiectasia mutated ATM a primary mediator of the DNA damage response as a potential target of miR-203; Using TCGA database we identified a significant reverse correlation of miR-203 and ATM expression in CRC tissues; We validated ATM as a bona fide target of miR-203 in CRC cells; Mutation of the putative miR-203 binding site in the 3' untranslated region 3'UTR of the ATM mRNA abolished the inhibitory effect of miR-203 on ATM;MiR 203 inhibits tumor invasion and metastasis in gastric cancer by ATM; Our results showed that miR-203 was significantly downregulated in gastric cancer tissues and cells while ataxia telangiectasia mutated kinase ATM was upregulated in gastric cancer tissues and cells and was directly regulated by miR-203; ATM knockdown phenocopied the effect of miR-203 overexpression
9 hsa-miR-27a-5p ATM 1.45 0.03942 -0.66 0.11688 MirTarget -0.12 0.00046 NA
10 hsa-miR-30e-3p ATM -0.04 0.93258 -0.66 0.11688 mirMAP -0.16 0.0051 NA
11 hsa-miR-339-5p ATM 1.23 0.03075 -0.66 0.11688 miRanda -0.16 0.00017 NA
12 hsa-miR-590-5p ATM 1.51 0.00239 -0.66 0.11688 mirMAP -0.13 0.00485 NA
13 hsa-miR-29a-5p ATR 0.07 0.88413 1.12 0.00118 mirMAP -0.13 0.00077 NA
14 hsa-miR-30a-5p ATR -0.77 0.32049 1.12 0.00118 mirMAP -0.11 1.0E-5 NA
15 hsa-miR-139-5p BBC3 -2.09 0.00038 0.48 0.3579 miRNATAP -0.16 0.00143 NA
16 hsa-let-7a-5p CCND1 0.15 0.64531 0.15 0.87753 TargetScan; miRNATAP -0.54 0.00245 NA
17 hsa-miR-106a-5p CCND1 3.99 0 0.15 0.87753 MirTarget; miRNATAP -0.43 0 NA
18 hsa-miR-15a-5p CCND1 2.05 0 0.15 0.87753 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.35 0.00776 22922827 CCND1 has been found to be a target of miR-15a and miR-16-1 through analysis of complementary sequences between microRNAs and CCND1 mRNA; Moreover the transcription of CCND1 is suppressed by miR-15a and miR-16-1 via direct binding to the CCND1 3'-untranslated region 3'-UTR
19 hsa-miR-15b-5p CCND1 3.32 0 0.15 0.87753 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.42 0.00029 NA
20 hsa-miR-20b-5p CCND1 4.57 5.0E-5 0.15 0.87753 MirTarget; miRNATAP -0.31 0 NA
21 hsa-miR-34a-5p CCND1 0.83 0.04775 0.15 0.87753 miRNAWalker2 validate; miRTarBase; miRNATAP -0.42 0.00174 25792709; 21399894 This inhibition of proliferation was associated with a decrease in cyclin D1 levels orchestrated principally by HNF-4α a target of miR-34a considered to act as a tumour suppressor in the liver;Quantitative PCR and western analysis confirmed decreased expression of two genes BCL-2 and CCND1 in docetaxel-resistant cells which are both targeted by miR-34a
22 hsa-miR-497-5p CCND1 -1.44 0.02251 0.15 0.87753 MirTarget; miRNATAP -0.25 0.00498 21350001 Raf-1 and Ccnd1 were identified as novel direct targets of miR-195 and miR-497 miR-195/497 expression levels in clinical specimens were found to be correlated inversely with malignancy of breast cancer
23 hsa-miR-106a-5p CCND2 3.99 0 -2.81 0.0014 miRNATAP -0.44 0 NA
24 hsa-miR-106b-5p CCND2 2.81 0 -2.81 0.0014 miRNAWalker2 validate; miRTarBase; miRNATAP -0.31 0.00374 NA
25 hsa-miR-10a-3p CCND2 0.97 0.31667 -2.81 0.0014 mirMAP -0.2 0.00011 NA
26 hsa-miR-130b-5p CCND2 3.74 0 -2.81 0.0014 mirMAP -0.46 0 NA
27 hsa-miR-141-3p CCND2 7.3 0 -2.81 0.0014 MirTarget; TargetScan -0.24 0.00021 NA
28 hsa-miR-15b-5p CCND2 3.32 0 -2.81 0.0014 miRNATAP -0.53 0 NA
29 hsa-miR-16-2-3p CCND2 3.8 0 -2.81 0.0014 mirMAP -0.29 0.00207 NA
30 hsa-miR-182-5p CCND2 5.87 0 -2.81 0.0014 miRNAWalker2 validate; miRTarBase; miRNATAP -0.28 2.0E-5 NA
31 hsa-miR-183-5p CCND2 6.62 0 -2.81 0.0014 miRNATAP -0.29 0 NA
32 hsa-miR-191-5p CCND2 1.59 0.00074 -2.81 0.0014 MirTarget -0.32 0.00314 NA
33 hsa-miR-200a-3p CCND2 6.34 0 -2.81 0.0014 MirTarget -0.41 0 NA
34 hsa-miR-20b-5p CCND2 4.57 5.0E-5 -2.81 0.0014 miRNATAP -0.3 0 NA
35 hsa-miR-224-3p CCND2 2.85 0.00018 -2.81 0.0014 mirMAP -0.22 0.00101 NA
36 hsa-miR-28-5p CCND2 -0.82 0.02212 -2.81 0.0014 miRanda -0.43 0.00273 NA
37 hsa-miR-3065-3p CCND2 1.89 0.03082 -2.81 0.0014 MirTarget; miRNATAP -0.21 0.00027 NA
38 hsa-miR-3065-5p CCND2 2.14 0.06094 -2.81 0.0014 mirMAP -0.2 0.00026 NA
39 hsa-miR-30d-3p CCND2 -0.07 0.85742 -2.81 0.0014 mirMAP -0.55 1.0E-5 NA
40 hsa-miR-324-3p CCND2 1.51 0.00384 -2.81 0.0014 miRNAWalker2 validate -0.44 0 NA
41 hsa-miR-33a-3p CCND2 2.06 0.00156 -2.81 0.0014 MirTarget -0.27 0.00041 NA
42 hsa-miR-378a-3p CCND2 1.47 0.04667 -2.81 0.0014 miRNAWalker2 validate -0.19 0.00601 NA
43 hsa-miR-429 CCND2 6.4 0 -2.81 0.0014 miRNATAP -0.46 0 NA
44 hsa-miR-497-5p CCND2 -1.44 0.02251 -2.81 0.0014 MirTarget; miRNATAP -0.27 0.00058 NA
45 hsa-miR-550a-5p CCND2 1.22 0.06138 -2.81 0.0014 MirTarget -0.22 0.00363 NA
46 hsa-miR-660-5p CCND2 -0.07 0.88525 -2.81 0.0014 mirMAP -0.29 0.00793 NA
47 hsa-miR-9-3p CCND2 1.69 0.12517 -2.81 0.0014 MirTarget; mirMAP; miRNATAP -0.14 0.00185 NA
48 hsa-miR-93-5p CCND2 2.66 0 -2.81 0.0014 miRNATAP -0.48 0 NA
49 hsa-miR-96-5p CCND2 5.63 0 -2.81 0.0014 TargetScan; miRNATAP -0.24 0.0003 NA
50 hsa-miR-27b-3p CCND3 -0.09 0.85847 -0.54 0.12437 miRNAWalker2 validate -0.14 0.00019 NA
51 hsa-miR-429 CCND3 6.4 0 -0.54 0.12437 miRNATAP -0.11 1.0E-5 NA
52 hsa-miR-96-5p CCND3 5.63 0 -0.54 0.12437 TargetScan -0.12 1.0E-5 NA
53 hsa-miR-125b-5p CCNE1 -2.01 0.00516 3.91 0 miRNAWalker2 validate -0.13 0.00065 NA
54 hsa-miR-195-5p CCNE1 -1.59 0.01691 3.91 0 miRNAWalker2 validate; MirTarget; miRNATAP -0.12 0.0047 24402230 Furthermore through qPCR and western blot assays we showed that overexpression of miR-195-5p reduced CCNE1 mRNA and protein levels respectively
55 hsa-miR-26a-5p CCNE1 -0.35 0.36204 3.91 0 miRNAWalker2 validate; miRTarBase; miRNATAP -0.18 0.00988 22094936 Cell cycle regulation and CCNE1 and CDC2 were the only significant overlapping pathway and genes differentially expressed between tumors with high and low levels of miR-26a and EZH2 respectively; Low mRNA levels of EZH2 CCNE1 and CDC2 and high levels of miR-26a are associated with favorable outcome on tamoxifen
56 hsa-miR-497-5p CCNE1 -1.44 0.02251 3.91 0 MirTarget; miRNATAP -0.13 0.00315 24909281; 24112607; 25909221 miR 497 suppresses proliferation of human cervical carcinoma HeLa cells by targeting cyclin E1; Furthermore the target effect of miR-497 on the CCNE1 was identified by dual-luciferase reporter assay system qRT-PCR and Western blotting; Over-expressed miR-497 in HeLa cells could suppress cell proliferation by targeting CCNE1;Western blot assays confirmed that overexpression of miR-497 reduced cyclin E1 protein levels; Inhibited cellular growth suppressed cellular migration and invasion and G1 cell cycle arrest were observed upon overexpression of miR-497 in cells possibly by targeting cyclin E1;The effect of simultaneous overexpression of miR-497 and miR-34a on the inhibition of cell proliferation colony formation and tumor growth and the downregulation of cyclin E1 was stronger than the effect of each miRNA alone; The synergistic actions of miR-497 and miR-34a partly correlated with cyclin E1 levels; These results indicate cyclin E1 is downregulated by both miR-497 and miR-34a which synergistically retard the growth of human lung cancer cells
57 hsa-miR-28-3p CCNE2 -0.99 0.01882 4.78 0 PITA; miRNATAP -0.21 0.00739 NA
58 hsa-miR-30a-5p CCNE2 -0.77 0.32049 4.78 0 miRNATAP -0.23 0 NA
59 hsa-miR-142-3p CCNG1 4.35 0 -1.1 0.00346 miRanda -0.1 0.00059 NA
60 hsa-miR-142-5p CCNG1 3.96 0 -1.1 0.00346 mirMAP -0.13 1.0E-5 NA
61 hsa-miR-21-5p CCNG1 2.65 0 -1.1 0.00346 miRNAWalker2 validate -0.22 0.00035 NA
62 hsa-miR-23a-3p CCNG1 0.93 0.01273 -1.1 0.00346 MirTarget; miRNATAP -0.2 0.00054 NA
63 hsa-miR-24-3p CCNG1 1.56 0.00052 -1.1 0.00346 miRNAWalker2 validate -0.17 0.00038 NA
64 hsa-miR-27a-3p CCNG1 1.76 0.00022 -1.1 0.00346 MirTarget; miRNATAP -0.25 0 NA
65 hsa-miR-27b-3p CCNG1 -0.09 0.85847 -1.1 0.00346 MirTarget; miRNATAP -0.11 0.00875 26623719 Moreover miR-27b directly targets the 3' untranslated regions 3'-UTRs of CCNG1 a well-known negative regulator of P53 stability; Interestingly miR-27b up-regulation leads to increased miR-508-5p expression and this phenomenon is mediated by CCNG1 and P53
66 hsa-miR-16-2-3p CCNG2 3.8 0 -0.75 0.10471 mirMAP -0.13 0.00819 NA
67 hsa-miR-664a-3p CCNG2 0.25 0.56171 -0.75 0.10471 MirTarget; mirMAP -0.26 2.0E-5 NA
68 hsa-miR-125a-3p CD82 -0.07 0.92074 2.27 0.00065 miRanda -0.15 0.00239 NA
69 hsa-miR-491-5p CD82 0.57 0.31331 2.27 0.00065 miRanda -0.25 0.00028 NA
70 hsa-miR-140-5p CDK2 -0.63 0.12667 1.42 2.0E-5 miRanda -0.12 0.00814 NA
71 hsa-let-7a-5p CDK6 0.15 0.64531 0.5 0.55124 miRNAWalker2 validate; miRTarBase; TargetScan -0.65 2.0E-5 NA
72 hsa-let-7b-5p CDK6 -0.19 0.65188 0.5 0.55124 miRNAWalker2 validate; miRTarBase -0.47 5.0E-5 NA
73 hsa-miR-101-3p CDK6 -1.12 0.02009 0.5 0.55124 mirMAP -0.42 2.0E-5 NA
74 hsa-miR-106a-5p CDK6 3.99 0 0.5 0.55124 mirMAP -0.39 0 NA
75 hsa-miR-141-3p CDK6 7.3 0 0.5 0.55124 TargetScan; miRNATAP -0.2 0.0009 NA
76 hsa-miR-148b-3p CDK6 1.76 0 0.5 0.55124 mirMAP -0.47 0.00118 NA
77 hsa-miR-200a-3p CDK6 6.34 0 0.5 0.55124 miRNATAP -0.35 0 24009066 microRNA 200a is an independent prognostic factor of hepatocellular carcinoma and induces cell cycle arrest by targeting CDK6
78 hsa-miR-200b-3p CDK6 5.56 0 0.5 0.55124 mirMAP -0.39 0 NA
79 hsa-miR-20b-5p CDK6 4.57 5.0E-5 0.5 0.55124 mirMAP -0.28 0 26166554 The transfection of miR-20b into EJ cells induced G1 phase cell cycle arrest via the decreased expression of cyclin D1 CDK2 and CDK6 without affecting another G1 phase cell cycle regulator cyclin E
80 hsa-miR-30a-5p CDK6 -0.77 0.32049 0.5 0.55124 mirMAP -0.17 0.00517 NA
81 hsa-miR-30d-5p CDK6 0.3 0.38019 0.5 0.55124 mirMAP -0.5 0.00043 NA
82 hsa-miR-30e-5p CDK6 0.78 0.03467 0.5 0.55124 mirMAP -0.54 4.0E-5 NA
83 hsa-miR-34a-5p CDK6 0.83 0.04775 0.5 0.55124 miRNAWalker2 validate; miRTarBase; miRNATAP -0.36 0.00175 21702042; 26104764 Molecular analyses identified Cdk6 and sirtuin SIRT-1 as being targeted by miR-34a in MI-TCC cells however inhibition of Cdk6 and SIRT-1 was not as effective as pre-miR-34a in mediating chemosensitization;The expression of microRNA 34a is inversely correlated with c MET and CDK6 and has a prognostic significance in lung adenocarcinoma patients; We found significant inverse correlations between miR-34a and c-MET R = -0.316 P = 0.028 and CDK6 expression R = -0.4582 P = 0.004
84 hsa-miR-362-5p CDK6 -1.22 0.04527 0.5 0.55124 mirMAP -0.29 0.00026 NA
85 hsa-miR-429 CDK6 6.4 0 0.5 0.55124 mirMAP; miRNATAP -0.25 4.0E-5 NA
86 hsa-miR-497-5p CDK6 -1.44 0.02251 0.5 0.55124 miRNATAP -0.31 3.0E-5 NA
87 hsa-miR-502-3p CDK6 -0.1 0.80889 0.5 0.55124 PITA; miRNATAP -0.42 0.00027 NA
88 hsa-miR-592 CDK6 2.8 0.02935 0.5 0.55124 mirMAP -0.23 0 NA
89 hsa-miR-660-5p CDK6 -0.07 0.88525 0.5 0.55124 mirMAP -0.37 0.00036 NA
90 hsa-let-7e-5p CDKN1A -0.11 0.81474 0.58 0.35758 MirTarget -0.27 0.00026 NA
91 hsa-let-7g-5p CDKN1A 0.86 0.00648 0.58 0.35758 MirTarget -0.32 0.00586 NA
92 hsa-miR-125a-5p CDKN1A -1.32 0.00714 0.58 0.35758 miRNAWalker2 validate; miRTarBase -0.35 0 NA
93 hsa-miR-28-5p CDKN1A -0.82 0.02212 0.58 0.35758 miRNAWalker2 validate; miRTarBase; MirTarget; miRanda; miRNATAP -0.55 0 NA
94 hsa-miR-30b-3p CDKN1A 0.17 0.76608 0.58 0.35758 MirTarget -0.16 0.00864 NA
95 hsa-miR-335-5p CDKN1A 0.17 0.8039 0.58 0.35758 miRNAWalker2 validate -0.25 0 NA
96 hsa-miR-345-5p CDKN1A 2.77 4.0E-5 0.58 0.35758 miRNAWalker2 validate; miRTarBase; MirTarget -0.23 1.0E-5 NA
97 hsa-miR-423-3p CDKN1A 1.71 2.0E-5 0.58 0.35758 miRNAWalker2 validate; miRTarBase -0.27 0.00253 NA
98 hsa-miR-505-5p CDKN1A -0.55 0.33141 0.58 0.35758 miRNAWalker2 validate; MirTarget -0.18 0.00519 NA
99 hsa-miR-616-5p CDKN1A 2.48 0.00318 0.58 0.35758 mirMAP -0.14 0.0061 NA
100 hsa-miR-96-5p CDKN1A 5.63 0 0.58 0.35758 miRNAWalker2 validate; miRTarBase -0.17 0.00034 26582573 Upregulation of microRNA 96 and its oncogenic functions by targeting CDKN1A in bladder cancer; Bioinformatics prediction combined with luciferase reporter assay were used to verify whether the cyclin-dependent kinase inhibitor CDKN1A was a potential target gene of miR-96; According to the data of miRTarBase CDKN1A might be a candidate target gene of miR-96; In addition luciferase reporter and Western blot assays respectively demonstrated that miR-96 could bind to the putative seed region in CDKN1A mRNA 3'UTR and significantly reduce the expression level of CDKN1A protein; Moreover we found that the inhibition of miR-96 expression remarkably decreased cell proliferation and promoted cell apoptosis of BC cell lines which was consistent with the findings observed following the introduction of CDKN1A cDNA without 3'UTR restored miR-96; Upregulation of miR-96 may contribute to aggressive malignancy partly through suppressing CDKN1A protein expression in BC cells
101 hsa-miR-10b-5p CDKN2A -3.08 0 7.38 0 miRNAWalker2 validate; miRTarBase -0.36 0.00054 NA
102 hsa-miR-125a-5p CDKN2A -1.32 0.00714 7.38 0 miRanda -0.39 0.00048 NA
103 hsa-miR-106a-5p FAS 3.99 0 -0.34 0.58934 miRNAWalker2 validate; miRTarBase -0.14 0.00128 22431000; 27142596 miR 106a is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS; Bioinformatic analysis combining with validation experiments identified FAS as a direct target of miR-106a; Moreover a significant inverse correlation was found between miR-106a and FAS expression not only in gastric cancer cell lines but also in gastric cancer specimens; Taken together these findings suggest that ectopicly overexpressed miR-106a may play an oncogenic role in gastric carcinogenesis and impair extrinsic apoptotic pathway through targeting FAS;Functional experiment ascertained that miR-106a interacted with FAS and mediated caspase3 pathway
104 hsa-miR-361-5p FAS 0.01 0.9852 -0.34 0.58934 miRanda -0.33 0.00172 NA
105 hsa-miR-590-5p FAS 1.51 0.00239 -0.34 0.58934 miRanda -0.2 0.00636 NA
106 hsa-miR-129-5p GADD45A -2.67 0.00696 -0.57 0.35686 miRanda -0.1 0.00449 NA
107 hsa-miR-130b-3p GADD45A 3.92 0 -0.57 0.35686 MirTarget; miRNATAP -0.17 0.00324 NA
108 hsa-miR-146b-5p GADD45A 1.88 0.00074 -0.57 0.35686 miRanda -0.19 0.00233 NA
109 hsa-miR-148b-3p GADD45A 1.76 0 -0.57 0.35686 MirTarget -0.53 0 NA
110 hsa-miR-301a-3p GADD45A 1.99 0.00081 -0.57 0.35686 MirTarget; miRNATAP -0.19 0.00099 NA
111 hsa-miR-362-5p GADD45A -1.22 0.04527 -0.57 0.35686 MirTarget; PITA; miRNATAP -0.17 0.00222 NA
112 hsa-miR-375 GADD45A 3.38 0.04499 -0.57 0.35686 miRanda -0.1 0 NA
113 hsa-miR-454-3p GADD45A 1.4 0.00366 -0.57 0.35686 MirTarget; miRNATAP -0.31 2.0E-5 NA
114 hsa-miR-500a-5p GADD45A 0.02 0.97396 -0.57 0.35686 MirTarget; miRNATAP -0.19 0.00426 NA
115 hsa-miR-500b-5p GADD45A 0.02 0.9745 -0.57 0.35686 MirTarget -0.19 0.0043 NA
116 hsa-miR-324-3p GADD45B 1.51 0.00384 -1.88 0.00169 MirTarget; miRNATAP -0.17 0.00883 NA
117 hsa-miR-1976 GADD45G 3.27 0 -3.78 1.0E-5 MirTarget -0.34 0.0007 NA
118 hsa-miR-139-5p GTSE1 -2.09 0.00038 6.13 0 miRanda -0.15 0.0074 NA
119 hsa-let-7f-1-3p IGF1 1.62 0.00069 -4.48 0.00149 mirMAP -0.92 0 NA
120 hsa-miR-103a-2-5p IGF1 2.77 0.0003 -4.48 0.00149 mirMAP -0.61 0 NA
121 hsa-miR-130b-3p IGF1 3.92 0 -4.48 0.00149 MirTarget -0.48 0.00036 NA
122 hsa-miR-15b-3p IGF1 3.58 0 -4.48 0.00149 mirMAP -0.73 0 NA
123 hsa-miR-16-1-3p IGF1 2.83 0 -4.48 0.00149 mirMAP -0.81 0 NA
124 hsa-miR-19a-3p IGF1 2.17 0.00122 -4.48 0.00149 MirTarget -0.58 0 NA
125 hsa-miR-19b-1-5p IGF1 1.51 0.00147 -4.48 0.00149 mirMAP -1.02 0 NA
126 hsa-miR-19b-3p IGF1 1.68 0.00086 -4.48 0.00149 MirTarget -0.83 0 NA
127 hsa-miR-20a-3p IGF1 1.99 0.00062 -4.48 0.00149 mirMAP -0.77 0 NA
128 hsa-miR-27a-3p IGF1 1.76 0.00022 -4.48 0.00149 miRNAWalker2 validate; miRTarBase -1.1 0 NA
129 hsa-miR-301a-3p IGF1 1.99 0.00081 -4.48 0.00149 MirTarget -0.46 0.00055 NA
130 hsa-miR-32-3p IGF1 2.2 0.03928 -4.48 0.00149 mirMAP -0.55 3.0E-5 NA
131 hsa-miR-33a-3p IGF1 2.06 0.00156 -4.48 0.00149 MirTarget -0.4 0.00118 NA
132 hsa-miR-452-5p IGF1 2.45 0.00115 -4.48 0.00149 MirTarget; mirMAP -0.29 0.00626 NA
133 hsa-miR-486-5p IGF1 1.11 0.30929 -4.48 0.00149 PITA; miRNATAP -0.35 0 NA
134 hsa-miR-576-5p IGF1 1.3 0.00649 -4.48 0.00149 PITA; mirMAP; miRNATAP -0.69 4.0E-5 NA
135 hsa-miR-629-5p IGF1 1.57 0.01157 -4.48 0.00149 mirMAP -0.43 0.0009 NA
136 hsa-miR-940 IGF1 3.78 5.0E-5 -4.48 0.00149 MirTarget; PITA; miRNATAP -0.34 0.00113 NA
137 hsa-miR-19a-3p IGFBP3 2.17 0.00122 -2.13 0.03278 MirTarget; miRNATAP -0.28 0.00071 NA
138 hsa-miR-19b-3p IGFBP3 1.68 0.00086 -2.13 0.03278 MirTarget; miRNATAP -0.34 0.00224 NA
139 hsa-miR-340-5p IGFBP3 1.41 0.00959 -2.13 0.03278 MirTarget -0.4 0.0001 NA
140 hsa-miR-140-5p MDM2 -0.63 0.12667 1.1 0.00278 miRanda -0.13 0.00854 NA
141 hsa-miR-26b-5p MDM2 0.31 0.46163 1.1 0.00278 miRNAWalker2 validate -0.17 0.00068 NA
142 hsa-miR-374b-5p MDM2 -0.11 0.76489 1.1 0.00278 mirMAP -0.2 0.00025 NA
143 hsa-miR-450a-5p MDM2 0.28 0.64237 1.1 0.00278 mirMAP -0.11 0.00254 NA
144 hsa-miR-151a-3p MDM4 0.37 0.37692 0.02 0.951 mirMAP -0.15 0.00087 NA
145 hsa-miR-152-3p MDM4 0.1 0.86744 0.02 0.951 MirTarget -0.13 5.0E-5 NA
146 hsa-miR-15b-3p MDM4 3.58 0 0.02 0.951 mirMAP -0.16 0 NA
147 hsa-miR-21-3p MDM4 3.5 0 0.02 0.951 MirTarget -0.17 0 NA
148 hsa-miR-222-5p MDM4 2.52 0.00142 0.02 0.951 mirMAP -0.11 0 NA
149 hsa-miR-27a-3p MDM4 1.76 0.00022 0.02 0.951 miRNATAP -0.22 0 NA
150 hsa-miR-374b-5p MDM4 -0.11 0.76489 0.02 0.951 mirMAP -0.16 0.00198 NA

Over-represented Gene Ontology Biological Process

NumGOOverlapSizeP ValueAdj. P Value
1 REGULATION OF CELL CYCLE 24 949 2.002e-21 9.317e-18
2 SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 13 127 3.175e-19 7.387e-16
3 CELL CYCLE 24 1316 3.977e-18 6.169e-15
4 CELL CYCLE PROCESS 22 1081 1.96e-17 2.28e-14
5 NEGATIVE REGULATION OF CELL CYCLE G1 S PHASE TRANSITION 11 98 8.281e-17 6.393e-14
6 CELL CYCLE CHECKPOINT 13 194 8.948e-17 6.393e-14
7 POSITIVE REGULATION OF CELL CYCLE 15 332 9.617e-17 6.393e-14
8 MITOTIC CELL CYCLE 19 766 1.887e-16 1.081e-13
9 CELLULAR RESPONSE TO STRESS 24 1565 2.09e-16 1.081e-13
10 REGULATION OF CELL CYCLE ARREST 11 108 2.514e-16 1.17e-13
11 G1 DNA DAMAGE CHECKPOINT 10 73 2.962e-16 1.253e-13
12 REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 16 470 6.383e-16 2.475e-13
13 REGULATION OF CELL DEATH 23 1472 8.409e-16 3.01e-13
14 CELL DEATH 20 1001 1.455e-15 4.37e-13
15 POSITIVE REGULATION OF CELL DEATH 17 605 1.503e-15 4.37e-13
16 POSITIVE REGULATION OF CELL CYCLE ARREST 10 85 1.466e-15 4.37e-13
17 POSITIVE REGULATION OF CELL CYCLE PROCESS 13 247 2.104e-15 5.759e-13
18 NEGATIVE REGULATION OF CELL CYCLE 15 433 4.895e-15 1.265e-12
19 REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 10 97 5.789e-15 1.418e-12
20 REGULATION OF CELL CYCLE G1 S PHASE TRANSITION 11 147 8.149e-15 1.649e-12
21 MITOTIC DNA INTEGRITY CHECKPOINT 10 100 7.934e-15 1.649e-12
22 NEGATIVE REGULATION OF CELL CYCLE PHASE TRANSITION 11 146 7.55e-15 1.649e-12
23 DNA INTEGRITY CHECKPOINT 11 146 7.55e-15 1.649e-12
24 REGULATION OF TRANSFERASE ACTIVITY 19 946 8.856e-15 1.717e-12
25 INTRINSIC APOPTOTIC SIGNALING PATHWAY 11 152 1.184e-14 2.204e-12
26 CELLULAR RESPONSE TO DNA DAMAGE STIMULUS 17 720 2.611e-14 4.673e-12
27 REGULATION OF KINASE ACTIVITY 17 776 8.833e-14 1.522e-11
28 POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 21 1492 2.177e-13 3.618e-11
29 NEGATIVE REGULATION OF MITOTIC CELL CYCLE 11 199 2.344e-13 3.636e-11
30 MITOTIC CELL CYCLE CHECKPOINT 10 139 2.306e-13 3.636e-11
31 REGULATION OF PROTEIN MODIFICATION PROCESS 22 1710 2.686e-13 4.031e-11
32 SIGNAL TRANSDUCTION IN RESPONSE TO DNA DAMAGE 9 96 3.606e-13 5.244e-11
33 APOPTOTIC SIGNALING PATHWAY 12 289 4.958e-13 6.991e-11
34 NEGATIVE REGULATION OF CELL CYCLE PROCESS 11 214 5.207e-13 7.125e-11
35 RESPONSE TO ABIOTIC STIMULUS 18 1024 5.556e-13 7.386e-11
36 REGULATION OF PHOSPHORUS METABOLIC PROCESS 21 1618 1.054e-12 1.363e-10
37 REGULATION OF CELL CYCLE PHASE TRANSITION 12 321 1.711e-12 2.152e-10
38 REGULATION OF CELL PROLIFERATION 20 1496 2.764e-12 3.384e-10
39 INTRACELLULAR SIGNAL TRANSDUCTION 20 1572 6.878e-12 8.206e-10
40 REGULATION OF MITOTIC CELL CYCLE 13 468 7.353e-12 8.345e-10
41 REGULATION OF APOPTOTIC SIGNALING PATHWAY 12 363 7.229e-12 8.345e-10
42 POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 16 876 9.153e-12 1.014e-09
43 REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 10 213 1.661e-11 1.797e-09
44 REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 20 1656 1.783e-11 1.843e-09
45 REGULATION OF PEPTIDASE ACTIVITY 12 392 1.77e-11 1.843e-09
46 RESPONSE TO OXYGEN LEVELS 11 311 3.004e-11 3.039e-09
47 REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 9 162 4.257e-11 4.215e-09
48 REGULATION OF CELL CYCLE PROCESS 13 558 6.571e-11 6.37e-09
49 CELL CYCLE G1 S PHASE TRANSITION 8 111 7.032e-11 6.416e-09
50 G1 S TRANSITION OF MITOTIC CELL CYCLE 8 111 7.032e-11 6.416e-09
51 POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 9 171 6.916e-11 6.416e-09
52 REGULATION OF PROTEOLYSIS 14 711 9.531e-11 8.528e-09
53 CELL CYCLE PHASE TRANSITION 10 255 9.786e-11 8.592e-09
54 AGING 10 264 1.375e-10 1.185e-08
55 NEGATIVE REGULATION OF CELL PROLIFERATION 13 643 3.761e-10 3.182e-08
56 POSITIVE REGULATION OF CATALYTIC ACTIVITY 18 1518 3.846e-10 3.196e-08
57 POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 16 1135 4.278e-10 3.492e-08
58 POSITIVE REGULATION OF CELL COMMUNICATION 18 1532 4.465e-10 3.582e-08
59 POSITIVE REGULATION OF MOLECULAR FUNCTION 19 1791 6.673e-10 5.262e-08
60 CELL CYCLE ARREST 8 154 9.731e-10 7.546e-08
61 ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY 7 95 1.027e-09 7.831e-08
62 POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 15 1036 1.239e-09 9.148e-08
63 POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 15 1036 1.239e-09 9.148e-08
64 INTRINSIC APOPTOTIC SIGNALING PATHWAY BY P53 CLASS MEDIATOR 6 53 1.261e-09 9.167e-08
65 REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 6 55 1.587e-09 1.136e-07
66 REGULATION OF RESPONSE TO STRESS 17 1468 2.07e-09 1.459e-07
67 POSITIVE REGULATION OF RESPONSE TO STIMULUS 19 1929 2.335e-09 1.622e-07
68 NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS 15 1087 2.392e-09 1.637e-07
69 REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 5 28 3.027e-09 2.041e-07
70 CELLULAR RESPONSE TO ABIOTIC STIMULUS 9 263 3.13e-09 2.081e-07
71 ZYMOGEN ACTIVATION 7 112 3.279e-09 2.149e-07
72 POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 9 289 7.122e-09 4.603e-07
73 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE 6 71 7.65e-09 4.876e-07
74 REPLICATIVE SENESCENCE 4 12 8.213e-09 5.164e-07
75 DNA REPLICATION 8 208 1.042e-08 6.466e-07
76 REGULATION OF CELLULAR RESPONSE TO STRESS 12 691 1.124e-08 6.879e-07
77 POSITIVE REGULATION OF DNA DAMAGE RESPONSE SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 4 13 1.184e-08 7.158e-07
78 RESPONSE TO DRUG 10 431 1.547e-08 9.226e-07
79 RESPONSE TO IONIZING RADIATION 7 145 1.986e-08 1.17e-06
80 CELL DIVISION 10 460 2.861e-08 1.654e-06
81 REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 7 153 2.879e-08 1.654e-06
82 POSITIVE REGULATION OF PEPTIDASE ACTIVITY 7 154 3.012e-08 1.709e-06
83 POSITIVE REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 4 17 3.919e-08 2.171e-06
84 POSITIVE REGULATION OF TRANSFERASE ACTIVITY 11 616 3.889e-08 2.171e-06
85 POSITIVE REGULATION OF KINASE ACTIVITY 10 482 4.438e-08 2.429e-06
86 POSITIVE REGULATION OF PROTEOLYSIS 9 363 5.09e-08 2.754e-06
87 CELLULAR RESPONSE TO EXTERNAL STIMULUS 8 264 6.637e-08 3.549e-06
88 NEGATIVE REGULATION OF CATALYTIC ACTIVITY 12 829 8.338e-08 4.409e-06
89 RESPONSE TO NITROGEN COMPOUND 12 859 1.227e-07 6.416e-06
90 NEGATIVE REGULATION OF CELL DEATH 12 872 1.444e-07 7.466e-06
91 RESPONSE TO RADIATION 9 413 1.527e-07 7.806e-06
92 NEGATIVE REGULATION OF MOLECULAR FUNCTION 13 1079 1.8e-07 9.106e-06
93 RESPONSE TO UV 6 126 2.416e-07 1.209e-05
94 RESPONSE TO EXTRACELLULAR STIMULUS 9 441 2.656e-07 1.315e-05
95 CELL AGING 5 67 2.801e-07 1.372e-05
96 PROTEIN STABILIZATION 6 131 3.043e-07 1.475e-05
97 DNA METABOLIC PROCESS 11 758 3.15e-07 1.511e-05
98 RESPONSE TO ESTROGEN 7 218 3.239e-07 1.538e-05
99 REGULATION OF PROTEIN STABILITY 7 221 3.553e-07 1.67e-05
100 REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 29 3.84e-07 1.769e-05
101 POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 29 3.84e-07 1.769e-05
102 CELLULAR RESPONSE TO RADIATION 6 137 3.964e-07 1.808e-05
103 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO DNA DAMAGE BY P53 CLASS MEDIATOR 4 30 4.424e-07 1.96e-05
104 NEGATIVE REGULATION OF CELL MATRIX ADHESION 4 30 4.424e-07 1.96e-05
105 RESPONSE TO X RAY 4 30 4.424e-07 1.96e-05
106 POSITIVE REGULATION OF MAPK CASCADE 9 470 4.534e-07 1.99e-05
107 CELLULAR RESPONSE TO OXYGEN LEVELS 6 143 5.103e-07 2.219e-05
108 NEGATIVE REGULATION OF TRANSFERASE ACTIVITY 8 351 5.829e-07 2.488e-05
109 INTRINSIC APOPTOTIC SIGNALING PATHWAY IN RESPONSE TO ENDOPLASMIC RETICULUM STRESS 4 32 5.788e-07 2.488e-05
110 REGULATION OF PROTEIN EXPORT FROM NUCLEUS 4 33 6.576e-07 2.782e-05
111 POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION 8 360 7.054e-07 2.957e-05
112 RESPONSE TO STEROID HORMONE 9 497 7.226e-07 3.002e-05
113 ORGAN REGENERATION 5 83 8.216e-07 3.353e-05
114 NEGATIVE REGULATION OF KINASE ACTIVITY 7 250 8.145e-07 3.353e-05
115 POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 36 9.423e-07 3.78e-05
116 POSITIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 4 36 9.423e-07 3.78e-05
117 REGENERATION 6 161 1.023e-06 4.069e-05
118 PROTEIN MATURATION 7 265 1.203e-06 4.742e-05
119 REGULATION OF CELL MATRIX ADHESION 5 90 1.23e-06 4.81e-05
120 ACTIVATION OF MAPKKK ACTIVITY 3 11 1.404e-06 5.445e-05
121 RESPONSE TO LIPID 11 888 1.501e-06 5.773e-05
122 REGULATION OF CELLULAR PROTEIN LOCALIZATION 9 552 1.723e-06 6.571e-05
123 NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 5 98 1.878e-06 7.103e-05
124 REGULATION OF EPITHELIAL CELL PROLIFERATION 7 285 1.951e-06 7.271e-05
125 REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY 4 43 1.953e-06 7.271e-05
126 NEGATIVE REGULATION OF PHOSPHORYLATION 8 422 2.314e-06 8.547e-05
127 NEGATIVE REGULATION OF RESPONSE TO STIMULUS 13 1360 2.489e-06 9.12e-05
128 RESPONSE TO NUTRIENT 6 191 2.764e-06 0.0001005
129 POSITIVE REGULATION OF P38MAPK CASCADE 3 14 3.084e-06 0.0001113
130 NEGATIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY 6 200 3.606e-06 0.0001291
131 NEGATIVE REGULATION OF CELL COMMUNICATION 12 1192 3.957e-06 0.0001406
132 CELLULAR RESPONSE TO IONIZING RADIATION 4 52 4.227e-06 0.0001479
133 NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS 9 616 4.227e-06 0.0001479
134 NEGATIVE REGULATION OF CELL SUBSTRATE ADHESION 4 53 4.565e-06 0.0001562
135 POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 4 53 4.565e-06 0.0001562
136 REGULATION OF INTRACELLULAR TRANSPORT 9 621 4.513e-06 0.0001562
137 NEGATIVE REGULATION OF PROTEOLYSIS 7 329 5.031e-06 0.0001704
138 RESPONSE TO ENDOGENOUS STIMULUS 13 1450 5.055e-06 0.0001704
139 REGULATION OF GROWTH 9 633 5.271e-06 0.0001765
140 POSITIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 3 17 5.737e-06 0.0001907
141 REGULATION OF MITOCHONDRION ORGANIZATION 6 218 5.918e-06 0.0001953
142 APOPTOTIC MITOCHONDRIAL CHANGES 4 57 6.12e-06 0.0002005
143 REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 6 220 6.236e-06 0.0002016
144 REGULATION OF DNA METABOLIC PROCESS 7 340 6.24e-06 0.0002016
145 NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY 5 126 6.467e-06 0.0002075
146 REGULATION OF CELL CYCLE G2 M PHASE TRANSITION 4 59 7.03e-06 0.0002225
147 REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION 5 128 6.984e-06 0.0002225
148 REGULATION OF MAPK CASCADE 9 660 7.386e-06 0.0002322
149 POSITIVE REGULATION OF PROTEIN EXPORT FROM NUCLEUS 3 19 8.151e-06 0.0002545
150 RESPONSE TO ENDOPLASMIC RETICULUM STRESS 6 233 8.659e-06 0.0002686
151 RESPONSE TO ALCOHOL 7 362 9.391e-06 0.0002894
152 NEGATIVE REGULATION OF CELL CYCLE ARREST 3 20 9.576e-06 0.0002931
153 POSITIVE REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS 4 64 9.74e-06 0.0002962
154 POSITIVE REGULATION OF INTRACELLULAR TRANSPORT 7 370 1.082e-05 0.000327
155 CELLULAR RESPONSE TO UV 4 66 1.102e-05 0.0003307
156 RESPONSE TO EXTERNAL STIMULUS 14 1821 1.168e-05 0.0003483
157 REGULATION OF HYDROLASE ACTIVITY 12 1327 1.185e-05 0.0003513
158 RESPONSE TO HORMONE 10 893 1.198e-05 0.0003527
159 POSITIVE REGULATION OF PROTEIN OLIGOMERIZATION 3 22 1.29e-05 0.0003728
160 RELEASE OF CYTOCHROME C FROM MITOCHONDRIA 3 22 1.29e-05 0.0003728
161 REGULATION OF RESPONSE TO DNA DAMAGE STIMULUS 5 145 1.281e-05 0.0003728
162 RESPONSE TO ESTRADIOL 5 146 1.324e-05 0.0003804
163 REGULATION OF MEMBRANE PERMEABILITY 4 70 1.393e-05 0.0003976
164 NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS 8 541 1.428e-05 0.0004028
165 NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS 8 541 1.428e-05 0.0004028
166 RESPONSE TO MAGNESIUM ION 3 23 1.481e-05 0.0004151
167 RESPONSE TO ORGANIC CYCLIC COMPOUND 10 917 1.508e-05 0.0004202
168 RESPONSE TO OXYGEN CONTAINING COMPOUND 12 1381 1.771e-05 0.0004906
169 POSITIVE REGULATION OF ORGANELLE ORGANIZATION 8 573 2.16e-05 0.0005891
170 RESPONSE TO CORTICOSTERONE 3 26 2.165e-05 0.0005891
171 REGULATION OF P38MAPK CASCADE 3 26 2.165e-05 0.0005891
172 REGULATION OF LEUKOCYTE APOPTOTIC PROCESS 4 79 2.251e-05 0.0006091
173 ACTIVATION OF PROTEIN KINASE ACTIVITY 6 279 2.403e-05 0.0006462
174 RESPONSE TO LIGHT STIMULUS 6 280 2.452e-05 0.0006556
175 REGULATION OF FIBROBLAST PROLIFERATION 4 81 2.486e-05 0.0006609
176 RESPONSE TO CARBOHYDRATE 5 168 2.607e-05 0.0006891
177 POSITIVE REGULATION OF LEUKOCYTE APOPTOTIC PROCESS 3 28 2.72e-05 0.000715
178 REGULATION OF CELL SUBSTRATE ADHESION 5 173 3e-05 0.0007843
179 POSITIVE REGULATION OF DNA REPLICATION 4 86 3.148e-05 0.0008184
180 RESPONSE TO CORTICOSTEROID 5 176 3.258e-05 0.0008421
181 NEGATIVE REGULATION OF B CELL ACTIVATION 3 30 3.361e-05 0.000864
182 RESPONSE TO KETONE 5 182 3.824e-05 0.0009776
183 CELLULAR RESPONSE TO LIGHT STIMULUS 4 91 3.933e-05 0.0009999
184 NEGATIVE REGULATION OF CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 3 32 4.094e-05 0.001033
185 MITOCHONDRIAL MEMBRANE ORGANIZATION 4 92 4.105e-05 0.001033
186 CELLULAR RESPONSE TO EXTRACELLULAR STIMULUS 5 188 4.464e-05 0.001117
187 REGULATION OF CELL AGING 3 33 4.497e-05 0.001119
188 PROTEIN KINASE B SIGNALING 3 34 4.925e-05 0.001212
189 NEGATIVE REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 3 34 4.925e-05 0.001212
190 NEGATIVE REGULATION OF PROTEIN PROCESSING 3 35 5.378e-05 0.001283
191 REGULATION OF PROTEIN OLIGOMERIZATION 3 35 5.378e-05 0.001283
192 NEURON APOPTOTIC PROCESS 3 35 5.378e-05 0.001283
193 RESPONSE TO MINERALOCORTICOID 3 35 5.378e-05 0.001283
194 NEGATIVE REGULATION OF PROTEIN MATURATION 3 35 5.378e-05 0.001283
195 REGULATION OF RESPONSE TO REACTIVE OXYGEN SPECIES 3 35 5.378e-05 0.001283
196 RESPONSE TO METAL ION 6 333 6.445e-05 0.00153
197 REGULATION OF GLUCOSE METABOLIC PROCESS 4 106 7.145e-05 0.001688
198 CELLULAR RESPONSE TO ESTROGEN STIMULUS 3 41 8.683e-05 0.002041
199 POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION 7 514 8.791e-05 0.002056
200 NEGATIVE REGULATION OF EPITHELIAL CELL PROLIFERATION 4 115 9.809e-05 0.002282
201 POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 10 1152 0.0001047 0.002424
202 REGULATION OF RELEASE OF CYTOCHROME C FROM MITOCHONDRIA 3 44 0.0001074 0.002474
203 POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 4 121 0.0001194 0.002724
204 REGULATION OF B CELL ACTIVATION 4 121 0.0001194 0.002724
205 POSITIVE REGULATION OF MITOTIC CELL CYCLE 4 123 0.0001273 0.002888
206 REGULATION OF PROTEIN LOCALIZATION 9 950 0.0001282 0.002895
207 NEGATIVE REGULATION OF GROWTH 5 236 0.0001306 0.002915
208 NEURON DEATH 3 47 0.0001309 0.002915
209 POSITIVE REGULATION OF NEURON APOPTOTIC PROCESS 3 47 0.0001309 0.002915
210 REGULATION OF INTRACELLULAR PROTEIN TRANSPORT 6 381 0.000135 0.002991
211 REGULATION OF SMOOTH MUSCLE CELL MIGRATION 3 49 0.0001483 0.003271
212 NEGATIVE REGULATION OF PEPTIDASE ACTIVITY 5 245 0.0001556 0.003415
213 RESPONSE TO GAMMA RADIATION 3 50 0.0001576 0.003442
214 REGULATION OF NEURON DEATH 5 252 0.0001774 0.003858
215 RESPONSE TO ETHANOL 4 136 0.0001874 0.004039
216 POSITIVE REGULATION OF FIBROBLAST PROLIFERATION 3 53 0.0001875 0.004039
217 REGULATION OF LYMPHOCYTE APOPTOTIC PROCESS 3 54 0.0001983 0.004231
218 CELL CYCLE G2 M PHASE TRANSITION 4 138 0.0001982 0.004231
219 REGULATION OF B CELL PROLIFERATION 3 55 0.0002094 0.004449
220 MITOCHONDRION ORGANIZATION 7 594 0.000215 0.004547
221 NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS 8 801 0.000225 0.004736
222 RAS PROTEIN SIGNAL TRANSDUCTION 4 143 0.0002271 0.00476
223 REGULATION OF TRANSPORT 12 1804 0.0002375 0.004955
224 REGULATION OF CELLULAR LOCALIZATION 10 1277 0.0002438 0.005063
225 REGULATION OF EPITHELIAL CELL APOPTOTIC PROCESS 3 59 0.0002579 0.005332
226 RESPONSE TO TRANSITION METAL NANOPARTICLE 4 148 0.000259 0.005332
227 DEOXYRIBONUCLEOTIDE BIOSYNTHETIC PROCESS 2 12 0.0002804 0.005722
228 POSITIVE REGULATION OF INSULIN LIKE GROWTH FACTOR RECEPTOR SIGNALING PATHWAY 2 12 0.0002804 0.005722
229 NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 6 437 0.0002833 0.005755
230 MITOTIC CELL CYCLE ARREST 2 13 0.0003309 0.006663
231 ACTIVATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY INVOLVED IN APOPTOTIC SIGNALING PATHWAY 2 13 0.0003309 0.006663
232 RESPONSE TO PURINE CONTAINING COMPOUND 4 158 0.0003322 0.006663
233 REGULATION OF JNK CASCADE 4 159 0.0003403 0.006795
234 REGULATION OF RESPONSE TO OXIDATIVE STRESS 3 65 0.0003436 0.006832
235 REGULATION OF DNA REPLICATION 4 161 0.0003568 0.007064
236 POSITIVE REGULATION OF NEURON DEATH 3 67 0.0003757 0.007407
237 MITOCHONDRIAL DNA METABOLIC PROCESS 2 14 0.0003856 0.007475
238 REGULATION OF FIBRINOLYSIS 2 14 0.0003856 0.007475
239 DETERMINATION OF ADULT LIFESPAN 2 14 0.0003856 0.007475
240 REGULATION OF SMOOTH MUSCLE CELL APOPTOTIC PROCESS 2 14 0.0003856 0.007475
241 POSITIVE REGULATION OF CELL CYCLE PHASE TRANSITION 3 68 0.0003925 0.007577
242 POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION 4 167 0.0004098 0.00788
243 DENTATE GYRUS DEVELOPMENT 2 15 0.0004443 0.008403
244 NEGATIVE REGULATION OF B CELL PROLIFERATION 2 15 0.0004443 0.008403
245 RESPONSE TO VITAMIN E 2 15 0.0004443 0.008403
246 RESPONSE TO BIOTIC STIMULUS 8 886 0.0004437 0.008403
247 REGULATION OF CARBOHYDRATE METABOLIC PROCESS 4 172 0.0004582 0.008631
248 RESPONSE TO INORGANIC SUBSTANCE 6 479 0.0004617 0.008662
249 DNA REPAIR 6 480 0.0004668 0.008723
250 REGULATION OF CYTOPLASMIC TRANSPORT 6 481 0.000472 0.008784
251 REGULATION OF CELL ACTIVATION 6 484 0.0004877 0.009041
252 NEGATIVE REGULATION OF ADHERENS JUNCTION ORGANIZATION 2 16 0.0005071 0.009253
253 NEGATIVE REGULATION OF SMOOTH MUSCLE CELL MIGRATION 2 16 0.0005071 0.009253
254 REGULATION OF PROTEIN HOMOOLIGOMERIZATION 2 16 0.0005071 0.009253
255 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 9 1142 0.000504 0.009253
256 MITOCHONDRIAL TRANSPORT 4 177 0.0005104 0.009278
257 REGULATION OF MAP KINASE ACTIVITY 5 319 0.0005245 0.009497
258 PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS 12 1977 0.0005529 0.009971
NumGOOverlapSizeP ValueAdj. P Value
1 CYCLIN DEPENDENT PROTEIN SERINE THREONINE KINASE REGULATOR ACTIVITY 5 28 3.027e-09 2.812e-06
2 KINASE BINDING 11 606 3.291e-08 1.529e-05
3 ENZYME BINDING 16 1737 1.834e-07 5.679e-05
4 KINASE REGULATOR ACTIVITY 6 186 2.37e-06 0.0005505
5 CYCLIN BINDING 3 19 8.151e-06 0.001515
6 P53 BINDING 4 67 1.17e-05 0.001811
7 PROTEIN COMPLEX BINDING 10 935 1.785e-05 0.002368
8 ENZYME REGULATOR ACTIVITY 10 959 2.221e-05 0.002579
9 PROTEIN SERINE THREONINE KINASE INHIBITOR ACTIVITY 3 30 3.361e-05 0.003469
10 CYCLIN DEPENDENT PROTEIN KINASE ACTIVITY 3 34 4.925e-05 0.004575
11 MACROMOLECULAR COMPLEX BINDING 11 1399 0.000107 0.009035
NumGOOverlapSizeP ValueAdj. P Value
1 CYCLIN DEPENDENT PROTEIN KINASE HOLOENZYME COMPLEX 7 31 2.695e-13 1.574e-10
2 PROTEIN KINASE COMPLEX 7 90 6.995e-10 2.043e-07
3 TRANSFERASE COMPLEX TRANSFERRING PHOSPHORUS CONTAINING GROUPS 7 237 5.691e-07 0.0001108

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 hsa04115_p53_signaling_pathway 42 69 3.731e-111 6.715e-109
2 hsa04110_Cell_cycle 16 128 4.35e-25 3.915e-23
3 hsa04151_PI3K_AKT_signaling_pathway 12 351 4.88e-12 2.928e-10
4 hsa04390_Hippo_signaling_pathway 6 154 7.887e-07 3.549e-05
5 hsa04510_Focal_adhesion 6 200 3.606e-06 0.0001298
6 hsa04210_Apoptosis 4 89 3.604e-05 0.001081
7 hsa04114_Oocyte_meiosis 4 114 9.482e-05 0.002438
8 hsa04010_MAPK_signaling_pathway 4 268 0.002365 0.05322
9 hsa04960_Aldosterone.regulated_sodium_reabsorption 2 42 0.003515 0.06873
10 hsa04310_Wnt_signaling_pathway 3 151 0.003904 0.06873
11 hsa04630_Jak.STAT_signaling_pathway 3 155 0.0042 0.06873
12 hsa00480_Glutathione_metabolism 2 50 0.004948 0.07421
13 hsa04914_Progesterone.mediated_oocyte_maturation 2 87 0.01439 0.1992
14 hsa00240_Pyrimidine_metabolism 2 99 0.01836 0.2361
15 hsa04650_Natural_killer_cell_mediated_cytotoxicity 2 136 0.0331 0.3972
16 hsa00230_Purine_metabolism 2 162 0.04545 0.5114

lncRNA-mediated sponge

(Download full result)

Num lncRNA miRNAs           miRNAs count     Gene Sponge regulatory network lncRNA log2FC lncRNA pvalue Gene log2FC Gene pvalue lncRNA-gene Pearson correlation
1

MAGI2-AS3

 hsa-miR-16-1-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-20a-5p;hsa-miR-3065-5p;hsa-miR-33a-3p;hsa-miR-500a-5p;hsa-miR-576-5p;hsa-miR-590-3p;hsa-miR-616-5p 13 THBS1 Sponge network -4.563 0 -3.751 0.0001 0.664
2

HAND2-AS1

 hsa-let-7f-1-3p;hsa-miR-103a-2-5p;hsa-miR-130b-3p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-27a-3p;hsa-miR-32-3p;hsa-miR-33a-3p;hsa-miR-486-5p;hsa-miR-629-5p;hsa-miR-940 15 IGF1 Sponge network -7.871 0 -4.485 0.00149 0.653
3

RP11-166D19.1

 hsa-miR-16-1-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-20a-5p;hsa-miR-33a-3p;hsa-miR-576-5p;hsa-miR-590-3p;hsa-miR-616-5p 11 THBS1 Sponge network -4.209 2.0E-5 -3.751 0.0001 0.639
4

EMX2OS

 hsa-let-7f-1-3p;hsa-miR-103a-2-5p;hsa-miR-130b-3p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-27a-3p;hsa-miR-32-3p;hsa-miR-452-5p;hsa-miR-486-5p;hsa-miR-629-5p;hsa-miR-940 14 IGF1 Sponge network -6.205 0.00015 -4.485 0.00149 0.631
5

MIR143HG

 hsa-miR-16-1-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-20a-5p;hsa-miR-3065-5p;hsa-miR-33a-3p;hsa-miR-576-5p;hsa-miR-590-3p;hsa-miR-616-5p 12 THBS1 Sponge network -6.51 0 -3.751 0.0001 0.603
6

DNM3OS

 hsa-miR-16-1-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-19b-3p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-20a-5p;hsa-miR-3065-5p;hsa-miR-33a-3p;hsa-miR-576-5p;hsa-miR-590-3p;hsa-miR-616-5p 13 THBS1 Sponge network -3.933 0.00059 -3.751 0.0001 0.584
7

RP11-389C8.2

 hsa-let-7f-1-3p;hsa-miR-130b-3p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-27a-3p;hsa-miR-301a-3p;hsa-miR-33a-3p 10 IGF1 Sponge network -3.089 2.0E-5 -4.485 0.00149 0.575
8

MAGI2-AS3

 hsa-let-7f-1-3p;hsa-miR-103a-2-5p;hsa-miR-130b-3p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-27a-3p;hsa-miR-301a-3p;hsa-miR-32-3p;hsa-miR-33a-3p;hsa-miR-576-5p;hsa-miR-629-5p;hsa-miR-940 16 IGF1 Sponge network -4.563 0 -4.485 0.00149 0.572
9

RP11-887P2.5

 hsa-let-7f-1-3p;hsa-miR-103a-2-5p;hsa-miR-130b-3p;hsa-miR-16-1-3p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-27a-3p;hsa-miR-486-5p;hsa-miR-576-5p;hsa-miR-940 11 IGF1 Sponge network -9.865 1.0E-5 -4.485 0.00149 0.567
10 AC003090.1 hsa-let-7f-1-3p;hsa-miR-103a-2-5p;hsa-miR-130b-3p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-27a-3p;hsa-miR-576-5p 11 IGF1 Sponge network -7.817 0.00161 -4.485 0.00149 0.561
11

MEG3

 hsa-let-7a-5p;hsa-miR-16-1-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-20a-5p;hsa-miR-33a-3p;hsa-miR-576-5p 10 THBS1 Sponge network -3.613 0.00075 -3.751 0.0001 0.544
12

MIR497HG

 hsa-let-7f-1-3p;hsa-miR-103a-2-5p;hsa-miR-130b-3p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-27a-3p;hsa-miR-301a-3p;hsa-miR-33a-3p;hsa-miR-940 13 IGF1 Sponge network -6.146 0.00024 -4.485 0.00149 0.518
13

ADAMTS9-AS1

 hsa-let-7f-1-3p;hsa-miR-103a-2-5p;hsa-miR-130b-3p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-27a-3p;hsa-miR-301a-3p;hsa-miR-576-5p;hsa-miR-629-5p;hsa-miR-940 14 IGF1 Sponge network -8.573 0.00012 -4.485 0.00149 0.499
14

WT1-AS

 hsa-let-7f-1-3p;hsa-miR-103a-2-5p;hsa-miR-130b-3p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-27a-3p;hsa-miR-301a-3p;hsa-miR-32-3p;hsa-miR-33a-3p;hsa-miR-576-5p;hsa-miR-629-5p;hsa-miR-940 16 IGF1 Sponge network -6.875 2.0E-5 -4.485 0.00149 0.493
15

MIR143HG

 hsa-let-7f-1-3p;hsa-miR-103a-2-5p;hsa-miR-130b-3p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-301a-3p;hsa-miR-33a-3p;hsa-miR-576-5p;hsa-miR-629-5p;hsa-miR-940 14 IGF1 Sponge network -6.51 0 -4.485 0.00149 0.49
16

DNM3OS

 hsa-let-7f-1-3p;hsa-miR-103a-2-5p;hsa-miR-130b-3p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-27a-3p;hsa-miR-301a-3p;hsa-miR-33a-3p;hsa-miR-576-5p;hsa-miR-940 14 IGF1 Sponge network -3.933 0.00059 -4.485 0.00149 0.483
17

RP11-166D19.1

 hsa-let-7f-1-3p;hsa-miR-130b-3p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-27a-3p;hsa-miR-33a-3p;hsa-miR-452-5p;hsa-miR-576-5p 12 IGF1 Sponge network -4.209 2.0E-5 -4.485 0.00149 0.477
18 AC005682.5 hsa-miR-106a-5p;hsa-miR-10a-3p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-182-5p;hsa-miR-191-5p;hsa-miR-200a-3p;hsa-miR-20b-5p;hsa-miR-28-5p;hsa-miR-3065-3p;hsa-miR-3065-5p 11 CCND2 Sponge network -2.193 0.07184 -2.811 0.0014 0.394
19 ZNF667-AS1 hsa-let-7f-1-3p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-27a-3p;hsa-miR-452-5p;hsa-miR-629-5p 10 IGF1 Sponge network -4.019 0.00137 -4.485 0.00149 0.383
20 RP11-244O19.1 hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-200a-3p;hsa-miR-3065-3p;hsa-miR-3065-5p;hsa-miR-30d-3p;hsa-miR-93-5p 12 CCND2 Sponge network -1.318 0.0924 -2.811 0.0014 0.383
21

FAM66C

 hsa-let-7f-1-3p;hsa-miR-103a-2-5p;hsa-miR-130b-3p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-20a-3p;hsa-miR-27a-3p;hsa-miR-940 10 IGF1 Sponge network -2.927 0.00012 -4.485 0.00149 0.38
22 DIO3OS hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-200a-3p;hsa-miR-20b-5p;hsa-miR-324-3p;hsa-miR-378a-3p 13 CCND2 Sponge network -4.295 0.00689 -2.811 0.0014 0.374
23

ACTA2-AS1

 hsa-miR-16-1-3p;hsa-miR-17-5p;hsa-miR-182-5p;hsa-miR-19b-3p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-20a-5p;hsa-miR-33a-3p;hsa-miR-576-5p;hsa-miR-590-3p 10 THBS1 Sponge network -6.142 0.00223 -3.751 0.0001 0.37
24

RP11-166D19.1

 hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-200a-3p;hsa-miR-20b-5p;hsa-miR-224-3p;hsa-miR-324-3p;hsa-miR-33a-3p;hsa-miR-378a-3p;hsa-miR-429;hsa-miR-550a-5p;hsa-miR-96-5p 18 CCND2 Sponge network -4.209 2.0E-5 -2.811 0.0014 0.339
25 RP11-439M11.1 hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-20b-5p;hsa-miR-324-3p 10 CCND2 Sponge network -2.662 0.21003 -2.811 0.0014 0.337
26

ACTA2-AS1

 hsa-let-7f-1-3p;hsa-miR-103a-2-5p;hsa-miR-130b-3p;hsa-miR-15b-3p;hsa-miR-16-1-3p;hsa-miR-19a-3p;hsa-miR-19b-1-5p;hsa-miR-19b-3p;hsa-miR-20a-3p;hsa-miR-27a-3p;hsa-miR-33a-3p;hsa-miR-576-5p 12 IGF1 Sponge network -6.142 0.00223 -4.485 0.00149 0.332
27

MAGI2-AS3

 hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-200a-3p;hsa-miR-20b-5p;hsa-miR-224-3p;hsa-miR-3065-5p;hsa-miR-30d-3p;hsa-miR-33a-3p;hsa-miR-378a-3p;hsa-miR-429;hsa-miR-9-3p;hsa-miR-93-5p 19 CCND2 Sponge network -4.563 0 -2.811 0.0014 0.315
28 RP11-284N8.3 hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-200a-3p;hsa-miR-3065-5p;hsa-miR-324-3p;hsa-miR-93-5p;hsa-miR-96-5p 10 CCND2 Sponge network -0.845 0.52848 -2.811 0.0014 0.313
29 GAS6-AS2 hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-200a-3p;hsa-miR-20b-5p;hsa-miR-28-5p;hsa-miR-3065-5p;hsa-miR-324-3p;hsa-miR-429 14 CCND2 Sponge network -1.941 0.0681 -2.811 0.0014 0.301
30

RP11-389C8.2

 hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-200a-3p;hsa-miR-224-3p;hsa-miR-3065-3p;hsa-miR-3065-5p;hsa-miR-33a-3p;hsa-miR-429;hsa-miR-550a-5p;hsa-miR-93-5p 17 CCND2 Sponge network -3.089 2.0E-5 -2.811 0.0014 0.293
31 RP11-554A11.4 hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-15b-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-20b-5p;hsa-miR-324-3p;hsa-miR-33a-3p 10 CCND2 Sponge network -5.361 2.0E-5 -2.811 0.0014 0.29
32

MIR143HG

 hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-200a-3p;hsa-miR-20b-5p;hsa-miR-224-3p;hsa-miR-3065-3p;hsa-miR-3065-5p;hsa-miR-30d-3p;hsa-miR-324-3p;hsa-miR-33a-3p;hsa-miR-378a-3p;hsa-miR-429;hsa-miR-550a-5p;hsa-miR-93-5p 21 CCND2 Sponge network -6.51 0 -2.811 0.0014 0.285
33 SOCS2-AS1 hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-200a-3p;hsa-miR-20b-5p;hsa-miR-324-3p;hsa-miR-33a-3p;hsa-miR-93-5p 12 CCND2 Sponge network -4.167 1.0E-5 -2.811 0.0014 0.258
34

RP11-597D13.9

 hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-200a-3p;hsa-miR-20b-5p;hsa-miR-30d-3p;hsa-miR-429;hsa-miR-93-5p;hsa-miR-96-5p 14 CCND2 Sponge network -2.494 0.07597 -2.811 0.0014 0.252
35

DNM3OS

 hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-5p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-183-5p;hsa-miR-191-5p;hsa-miR-200a-3p;hsa-miR-3065-3p;hsa-miR-3065-5p;hsa-miR-30d-3p;hsa-miR-33a-3p;hsa-miR-378a-3p;hsa-miR-429;hsa-miR-550a-5p;hsa-miR-93-5p;hsa-miR-96-5p 19 CCND2 Sponge network -3.933 0.00059 -2.811 0.0014 0.25

Quest ID: a0a4f741461fc7c9831466e8cc8572c7